India to supply of Covid-19 vaccines to 6 countries under grant assistance

Bhutan, Maldives, Bangladesh, Nepal, Myanmar and Seychelles are the countries that will receive the vaccines

Topics
Coronavirus Vaccine | Coronavirus | Bangladesh

Press Trust of India  |  New Delhi 

Coronavirus, vaccine, covid, drugs, clinical trials
Representational image

India on Tuesday announced that it will supply COVID-19 vaccines under grant assistance to Bhutan, Maldives, Bangladesh, Nepal, Myanmar and Seychelles from Wednesday.

The Ministry of External Affairs said India will supply COVID-19 vaccines to partner countries over the coming weeks and months in a phased manner keeping in view the domestic requirements.

It said India is awaiting confirmation of necessary regulatory clearances from Sri Lanka, Afghanistan and Mauritius for supply of the vaccines.

In a statement, the MEA said India has received several requests for the supply of Indian-manufactured vaccines from neighbouring and key partner countries.

"In response to these requests, and in keeping with India's stated commitment to use India's vaccine production and delivery capacity to help all of humanity fight the COVID pandemic, supplies under grant assistance to Bhutan, Maldives, Bangladesh, Nepal, Myanmar and Seychelles will begin from January 20," it said.

"In respect of Sri Lanka, Afghanistan and Mauritius, we are awaiting their confirmation of necessary regulatory clearances," it added.

India has already rolled out a massive vaccination drive under which two vaccines, Covishield and Covaxin, are being administered to frontline health workers across the country.

While Oxford-AstraZeneca's Covishield is being manufactured by the Serum Institute, and the Covaxin is being produced by Bharat Biotech.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on Coronavirus Vaccine
First Published: Tue, January 19 2021. 19:21 IST
RECOMMENDED FOR YOU